http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2484836-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_109aac041eb0be55d3f8aab6f37de565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_959571727611d1e6be2e07a980229b73 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dcd614e95a0018b0aa46cd6b83c68268 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fa545feb6e46fa605674bd6e02f9f956 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-28 |
| filingDate | 2011-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2013-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e4332f6ddaab4e3d1b49746778ebe87e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_58c2b511fa29c9c6d722ad5bd8cc6bbb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ffd57e77610ce01cfd8f658b66204a8f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_22f511524ca1c336147668764d009d3a |
| publicationDate | 2013-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2484836-C2 |
| titleOfInvention | Method of treating schizophrenia |
| abstract | FIELD: medicine. n SUBSTANCE: invention relates to medicine, namely to psychiatry, and concerns treating schizophrenia. That is ensured by administering a composite solution of cytokines which is prepared by arteriovenous perfusion of porcine spleen by physiological saline at a flow rate of 30-40 ml/min followed by sterilisation filtration and cryo-preservation. The cytokine solution is administered by inhalations in the form of a fine aerosol by a nebuliser in a dose of 10 ml/administration. Depending on the patient's initial state and the distinctions/severity of the disease for the first 3-5 days, the preparation is administered every 8 hours, then for 5-10 days - 1-2 times a day with a frequency of administration to be reduced to 1 time/3 days for 3 months with underlying total withdrawal of psychotropic agents. n EFFECT: administration of the cytokine solution which has a pronounced immunomodulatory effect in the developed regimen enhances the clinical effectiveness in the schizophrenic patients that manifests itself in the form of a pronounced reduction of the psychopathology by the scale PANSS and an induction of sustained remission lasting more than 6 months. n 1 ex, 2 tbl |
| priorityDate | 2011-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 241.